Phase 3 trials reveal retatrutide significantly reduces knee pain and weight in adults with knee osteoarthritis and obesity, with some patients pain-free by trial end. Additionally, a year-long study shows that combining Taltz and Zepbound improves disease control and metabolic outcomes in adults with psoriatic arthritis and obesity compared to Taltz alone. These findings highlight potential integrated treatments addressing both rheumatologic conditions and obesity, a common comorbidity that worsens patient outcomes. Lilly plans further research to advance therapies targeting immunometabolic health in these populations.
LLY (Eli Lilly And Co) shares are trading at USD 1,431.00, up 0.94% as of Nov 05, 2026 19:02 WIB on Pluang. The stock shows strong buying interest with 75% of orders as buys. Eli Lilly's market cap stands at $1.26 trillion, reflecting its significant presence in the health sector.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Eli Lilly is positioned as a key beneficiary of AI in drug discovery, using its scale and research capabilities to speed up new molecule development and expand its product portfolio. Despite a high forward price-to-earnings ratio of 40, the company i...
Eli Lilly reported a 39% increase in revenue driven by a 53% rise in volume, despite a 15% decline in realized prices. The company's gross margin improved to 83.9%, reflecting strong operational efficiency. Most revenue comes from the obesity drug ti...
Eli Lilly reported a robust third quarter with revenue up 38.6% to $24.4 billion, driven by a 53% increase in tirzepatide volume. CEO David Ricks emphasized growth beyond weight-loss drugs, highlighting advances in immunology, oncology, and neuroscie...
The AI-driven bull market faces challenges as investors rotate from high-spending tech stocks like Nvidia to traditionally defensive stocks such as Walmart and Eli Lilly. Despite strong earnings in some tech sectors, the Nasdaq-100 and semiconductor ...
